Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BC001 + TAS-102 in previously treated metastatic colorectal cancer
ChiCTR2300070070Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BC001 and trifluridine + tipiracil in metastatic colorectal adenocarcinoma (mCRC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety, Progression-free survival and 4 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
BC001trifluridine + tipiracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2300070070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070070.